Announced

Completed

CERo Therapeutics went public via a SPAC merger with Phoenix Biotech in a $50m deal.

Synopsis

CERo Therapeutics, an innovative immunotherapy company, went via a SPAC merger with Phoenix Biotech, a blank-check company, in a $50m deal. “We are thrilled to join forces with PBAX. With CERo technology we see an opportunity to engage the body’s full immune repertoire for optimized cellular immunotherapy. Chris and Brian bring a wealth of experience to the CERo team during this important time as we look to test the first CER T cell therapeutic candidate in the clinic," Daniel Corey, CERo CEO.

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US